A Randomized, Multicentre, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)
The purpose of this study is to show that maintenance therapy with nivolumab, or nivolumab
plus ipilimumab followed by nivolumab alone, will prolong Overall Survival and Progression
Free Survival compared with placebo in subjects with extensive stage disease small cell lung
cancer who have completed first line chemotherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society